Video

Dr. Weinberg on Broad Molecular Profiling in GI Cancers

Benjamin Weinberg, MD, assistant professor of medicine, Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, discusses the importance of broad molecular profiling in patients with gastrointestinal cancers.

Benjamin Weinberg, MD, assistant professor of medicine, Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, discusses the importance of broad molecular profiling in patients with gastrointestinal (GI) cancers.

Moving forward, clinicians are going to have to be more persistent about performing genetic testing in patients with these various tumor types. There are many genetic alterations that are highly rare, but if detected, they can be paired with effective therapies. NTRK is a good example of this, Weinberg says. Although these mutations only appear in approximately 1% of patients with GI cancers, physicians still need to look for them in every patient.

For example, larotrectinib (Vitrakvi) was approved by the FDA in November 2018 for use in patients with solid tumors that harbor NTRK fusions, and this drug is essentially a “silver bullet” for these patients. There are low rates of HER2 expression and microsatellite instability, as well, but these also have associated treatment options.

Other important molecular defects are homologous recombination deficiency and BRCA mutations, which can be inherited or acquired de novo. These patients have a higher likelihood of responding to platinum-based chemotherapy as well as PARP inhibitors, says Weinberg. As such, future research will be geared toward bringing PARP inhibitors to greater prominence in this space, Weinberg notes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity